Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
In patients with intermediate HCC, TACE-S was found to be more effective in terms of OS than TACE-L. No significant disparity was noted in PFS between the two treatment groups.
Authors
- Niansong Qian (ORCID: https://orcid.org/0000-0002-3297-4294)
- Mao Qiang Wang (ORCID: https://orcid.org/0009-0000-1981-6710)
- Jiamin Cheng
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-10-27
- DOI
- https://doi.org/10.1038/s41598-024-74801-x
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.74